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Abstract
Purpose To know which sperm selection technique, physiological intracytoplasmic sperm injection (PICSI) or magnetic-
activated cell sorting (MACS), is better for the selection of sperm with abnormal sperm DNA fragmentation (SDF) in patients
undergoing intracytoplasmic sperm injection (ICSI).
Methods A prospective randomized trial included 413 ICSI cases with abnormal SDF (> 20.3%) by TUNEL assay. Patients with
at least 1 million total progressive motile sperm count were randomized to PICSI or MACS groups on the day of ICSI. PICSI
depends on the hyaluronan binding of better SDF sperm where individual sperm was selected, while MACS selects non-
apoptotic sperm population using Annexin V magnetic beads. All pre-implantation embryogenic parameters were observed
and the main outcome was the ongoing pregnancy rate.
Results There were no significant differences between patients allocated to PICSI andMACS in the studied parameters including
pre-implantation embryological data, implantation, clinical pregnancy, and ongoing pregnancy rates. Meanwhile, sub-analysis
according to the female age has shown that female patients with less than 30 years of age in the MACS group had significantly
higher good-quality blastocyst, clinical pregnancy, and ongoing pregnancy rates than the PICSI group. However, the higher
implantation (p = 0.051), clinical pregnancy (p = 0.078), and ongoing pregnancy (p = 0.097) rates observed in females between
30 and 35 years of age in the PICSI group did not reach significance level.
Conclusions PICSI and MACS are efficient techniques for sperm selection in cases with abnormal sperm DNA fragmentation.
However, MACS is preferred when the females are younger than 30 years, while PICSI is preferred in older females.
Clinical trial registration number NCT03398317 (retrospectively registered)
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Introduction
The number of couples seeking infertility treatment is steadily
increasing [1]. Infertility affects about 10–15% of couples
worldwide [1] and 30–50% of the cases show a paternal cause
of infertility which may negatively affect the reproductive
outcomes [2, 3]. The management of male infertility can be
through treating the underlying causes or using a suitable
assisted reproductive technique like intracytoplasmic sperm
injection (ICSI) [2]. One of the main key determinants of
ICSI outcome is the quality of the embryo that develops after
the fertilization of oocytes with poor-quality sperm from in-
fertile men [4]. Conventional semen analysis is insufficient to
predict the male fertility potential or the success rate of ICSI
[3, 5, 6]. Sperm DNA fragmentation (SDF) is suggested to be
a major factor of male infertility [7–9] that negatively affects
fertilization [10], cleavage [10], blastulation [9, 10], implan-
tation [11], clinical pregnancy [8, 9], miscarriage [11–13], and
live birth rates [7] after in vitro fertilization (IVF) and ICSI.
On the other hand, there are indications that oocytes can repair
sperm DNA damage to a certain extent [14, 15] depending on
the oocyte quality, degree of sperm DNA fragmentation, and
time needed for repair [15].
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In vivo, sperm selection in the female genital tract starts from
the male germ cells being ejaculated into the upper part of the
vagina when the sperm have to move out the seminal plasma,
penetrate the cervical mucus, and move up the female genital
tract to meet the oocyte for fertilization in the ampulla of the
fallopian tube [16, 17]. This extremely stringent selection pro-
cess aims to select the most capable sperm with high DNA
integrity, maturity, and yields to successfully fertilize oocytes
and produce a good-quality embryo [16, 18]. Several natural
selection mechanisms can discriminate and select the best-
quality spermatozoa based on their characteristics [16].
However, in ICSI, all natural barriers for sperm selection, main-
ly the cumulus cell layer, the zona pellucida, and the oolemma,
are bypassed by injecting a single sperm into the oocyte. In turn,
bypassing these physiological selection barriers can impair fer-
tilization and embryo development [17]. Currently, the used
sperm preparation techniques like density gradient centrifuga-
tion (DGC) and swim-up depend on centrifugation and migra-
tion of the sperm [19], and have not been evaluated enough to
assess SDF’s impact on the clinical outcomes [19]; also, they
may include a centrifugation process that can negatively affect
SDF [20]. Therefore, several advanced sperm selection tech-
niques are developed tomimic the natural selectionmechanisms
[17, 19]; out of these techniques, we chose (I) elimination of
apoptotic sperm (magnetic-activated cell sorting—MACS) and
(II) membrane maturity (physiological ICSI—PICSI) [21, 22].
MACS is an effective tool to remove apoptotic sperm from
a sperm population [23, 24]. Annexin V specifically binds to
phosphatidylserine, which is externalized from the inner
membrane leaflet to the outer membrane leaflet if the mem-
brane structure is compromised, DNA integrity decreased, and
cells are labeling for abortive apoptosis [23]. Annexin V–
conjugated magnetic microbeads are used for magnetic sepa-
ration using MACS columns and separators yield a sperm
population with a lower incidence of apoptosis, higher nuclear
maturity [23, 24], higher count and lower SDF [25]. Some
studies showed improved fertilization, implantation rates,
and clinical pregnancy [26–28]. MACS can be done alone
or combined with DGC for extra selection and better repro-
ductive outcomes [23, 24, 28, 29].
Sperm selection using PICSI is based on the fact that only a
mature sperm head can bind to hyaluronan (HA), which is a
major component of cumulus oophorus and participates in the
natural sperm selection events [16]. Hyaluronan-bound sperm
are thought to reflect higher maturity, acrosome activity, as
well as lower aneuploidies and SDF [30, 31]. Hence, it is
thought to improve successful pre-implantation embryogene-
sis [19, 31, 32]. PICSI as a method of sperm selection is highly
specific and has minimal safety concerns [30].
The objective of this studywas to determine whichmethod,
PICSI or MACS, is better as a sperm selection technique for
patients with abnormal SDF undergoing ICSI in terms of their
clinical and pre-implantation embryogenic parameters.
Materials and methods
Study design and population
This study was approved by the Ethics Committee of Ganin
Fertility Center, Cairo, Egypt, for registration on www.
clinicaltrials.gov. Written consents were obtained from
patients prior to their inclusion in the study. A total of 413
patients attending Ganin Fertility Center from January 2017 to
March 2019 were included in the study for autologous ICSI
cycles. Patients were included in the study if the female age
was between 18 and 35 years and a minimum of 5 mature
oocytes were aspirated for injection. The male partners had
to have abnormal sperm SDF (cutoff value is 20.3%,
calculated according to the Egyptian population ROC study
[33]). The total progressive motile sperm count had to be at
least 1 million for the patient to be suitable for any of the used
sperm selection techniques. The exclusion criteria included
the presence of leukocytospermia, varicocele, or any factors
that affect ovarian stimulation or embryo implantation, and a
known genetic disorder. Patients were randomized on the day
of ICSI using computer software into two groups: the first
group: PICSI (n = 200); and the second group: MACS (n =
196); all participants and investigators except for
embryologists were masked to treatment allocation. The
primary outcome measures the ongoing pregnancy rate
(20 weeks of gestation), while the secondary outcomes
include cleavage rate (day 3), blastulation rate (day 5 or 6),
good-quality blastulation (day 5 or 6), clinical pregnancy
(14 days after embryo transfer), and the implantation rate
(6 weeks of gestation).
Sperm DNA fragmentation test
Sperm DNA fragmentation (SDF) was tested twice using the
TUNEL assay 3 weeks prior to ICSI procedure. Semen sam-
ples were collected after 1 to 2 days of sexual abstinence.
Following liquefaction for 30 min, semen samples underwent
a microscopic examination to evaluate sperm concentration,
motility, and normal morphology according to WHO (2010)
criteria.
In preparation for spermDNA fragmentation (SDF) assess-
ment, an aliquot of liquefied semen containing 5 million
sperm was washed in 1 ml phosphate-buffered saline (PBS;
Lonza, Verviers, Belgium) at 300×g for 4 min. The superna-
tant was discarded and the pellet fixed by re-suspension in
1 ml 3.7% paraformaldehyde (Sigma-Aldrich, Steinheim,
Germany) for 30min at 4 °C. Paraformaldehyde was removed
by centrifugation at 300×g for 4 min at room temperature, the
supernatant was discarded, and the cells in the pellet perme-
abilized by adding 1 ml of ice-cold 70% ethanol (CHEM-
LAB, Verviers, Belgium) for at least 30 min at − 20 °C.
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SDF was determined by means of the TUNEL assay kit
Apodirect (BD Pharmingen, San Diego, CA) using a BD
Accuri C6 bench-top flow cytometer (BD Pharmingen, San
Diego, CA). Positive and negative kit controls provided by the
manufacturer and internal controls (semen samples with known
DNA fragmentation) were included in each run. All samples
were washed twice with washing buffer containing 0.05% sodi-
um azide by centrifugation at 300×g for 5 min, followed by
adding 50 μl of freshly prepared staining solution containing
reaction buffer, FITC-dUTP, and TdT enzyme, followed by a
1-h incubation at 37 °C. Subsequently, the excess staining solu-
tion was removed by adding 1 ml rinsing buffer containing
0.05% sodium azide followed by centrifugation at 300×g for
5 min and discarding of the supernatant. The pellet was then
re-suspended in 0.5 ml propidium iodide (PI)/RNase Staining
Buffer (5 μg/ml, 200 μg/ml RNase) and incubated for 30 min at
room temperature, followed by flow cytometric analysis. For
each sample, 10,000 spermatozoa were counted and evaluated
for spermDNA fragmentation by the “Accuri C flow plus” flow
cytometer software (BD Pharmingen, San Diego, CA).
Controlled ovarian stimulation and oocyte pick up
The long protocol was preferred for ovulation stimulation in
all study cases, starting on day 3 of the menstrual cycle with
combined oral contraceptive pills Gynera® (Bayer,
Leverkusen, Germany) for 12–21 days, and 20 IU of
Lucrin® (Abbvie, Madrid, Spain) with an overlap of the last
5 days of Gynera®. From day 3 of the next cycle, downreg-
ulation was confirmed by endocrine profile and transvaginal
ultrasound. When confirmed, ovarian stimulation was started
using 150 IU Gonal-F® (Merck Serono, Rome, Italy) or
150 IU Fostimon® (IBSA, Collina d’Oro, Switzerland), com-
bined with 75 IU Menopur® (Ferring, Kiel, Germany). These
doses were adjusted in the following days according to each
patient’s response. When at least two follicles reached a mean
diameter of 19 mm or more, 10,000 IU of hCG (Pregnyl®;
Organon, Oss, The Netherlands) was intramuscularly injected.
Thirty-six hours after the hCG injection, oocytes were re-
trieved by ultrasound-guided transvaginal follicle aspiration
under general anesthesia. Cumulus-oocyte complexes were
collected in multipurpose handling medium MHM (Irvine
Scientific, CA, USA) supplemented with 10% serum substi-
tute supplement (SSS; Irvine Scientific). Cumulus-oocyte
complexes were washed and cultured in 50-μl drops of con-
tinuous single culture (CSC; Irvine Scientific) medium sup-
plemented with 10% SSS for denudation and ICSI procedure.
Sperm preparation and selection
All used sperm preparation and selection techniques were
tested before and do not have any adverse or unintended ef-
fects that may affect the trial outcomes.
Density gradient centrifugation
All semen samples were subjected to a double-layer density
gradient centrifugation using Isolate® (Irvine Scientific) with
1 ml of liquefied semen overlaying 50% and 90% discontin-
uous isolate layers in a 15-ml conical tube. Samples were
centrifuged at 250×g for 8 min at room temperature. After
centrifugation, the supernatant was aspirated with a Pasteur
pipette and the resulted soft pellet washed using Sperm wash
medium (Irvine Scientific) and centrifuged again at 250×g for
8 min at room temperature. The final pellet was re-suspended
in the residual volume to be ready for any of the assigned
sperm selection techniques.
Physiological ICSI
PICSI® dishes (Origio, Malov, Denmark) were prepared by
hydrating the hyaluronan microdots with 10 μl of MHM me-
dium with 10% SSS. Drops of 10% polyvinylpyrrolidone
(PVP) (Irvine Scientific) were placed elsewhere in the dish
for sperm immobilization. Few drops of MHM medium were
placed for oocyte injection. The dishes were covered with 3–
4 ml light mineral oil (Irvine Scientific) and incubated 10 min
at 30 °C for optimum sperm binding.
Magnetic-activated cell sorting
To perform MACS® (Miltenyi Biotec, Bergisch Gladbach,
Germany), the pellet after DGC was re-suspended and incu-
bated with 60-μl Annexin V–conjugated microbeads and
140 μl 1× binding buffer, followed by 20-min incubation at
room temperature in the dark. During the incubation, the
MiniMACS column (Miltenyi Biotec) was hanged on the
magnetic separator attached to the MACS stand and rinsed
with 0.5 ml 1× binding buffer to ensure optimum sperm bind-
ing. The sample was loaded onto the column and the eluted
portion was collected and evaluated for sperm count and
motility.
ICSI, embryo culture, and transfer
For every patient, all metaphase II (MII) oocytes were injected
2–4 h post oocyte pick up and then cultured in 25-μl drops of
CSC medium supplemented with 10% SSS in an incubator at
6% Co2, 5% O2, and 37 °C. According to the number and
quality of the cleaved embryos, the patient was set to transfer
on either day 3 or day 5. On day 5, embryos were morpho-
logically evaluated according to criteria described by Gardner
[34], where high-quality blastocyst are AA, AB, BA, and BB
regardless of their expansion degree. The blastulation rate is
calculated as the percentage of blastocysts formed on day 5 or
6 from the number of cleaved embryos. Embryo transfer was
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performed using a Wallace® embryo transfer catheter
(Origio) and abdominal ultrasound guidance.
Statistical analysis
As considering the primary outcome, sample size calculation
was done using the comparison of the ongoing pregnancy rate
between MACS and PICSI groups. Calculations were per-
formed based on comparing 2 proportions from independent
samples in a prospective study using the chi test, the α-error
level was fixed at 0.05, the power was set at 80%, and the
group’s ratio was set at 1. According to our pilot study, the
minimum optimum sample size should be 200 participants in
each arm to be able to reject the null hypothesis with the
assumed power. The calculation was done using PS Power
and Sample Size Calculations software, version 3.0.11 for
MS Windows.
All statistical calculations were done using IBM SPSS
(Statistical Package for the Social Sciences; IBM Corp,
Armonk, NY, USA) release 22 for Microsoft Windows.
Results are described in terms of mean ± standard deviation
(± SD) or frequencies (number of cases) and percentages
when appropriate. A comparison of numerical variables be-
tween the study groups was done using Student t test for
independent samples. For comparing categorical data, chi-
square (χ2) test was performed. A p value less than 0.05 was
considered statistically significant. A comparison of numeri-
cal variables between male age groups was done using a one-
way ANOVA test.
Results will include sub-analysis according to the male age
(less than 35 years, 36 to 41 years, and older than 41 years)
and female age (less than 30 years and from 30 to 35 years)
categories as described in previous studies [35–37].
Results
Between January 2017 and March 2019, 413 couples were
randomly assigned to receive PICSI or MACS. Seventeen
couples were excluded after randomization for mismatching
the inclusion criteria; 10 couples had leukocytospermia on the
day of ICSI, and 7 produced a smaller number ofMII oocytes.
Thus, 396 couples were included in the analysis PICSI (n =
200) and MACS (n = 196).
There were no significant differences between the PICSI
and MACS groups in female age, male age, primary/
secondary infertility, smoking status, sexual abstinence days,
SDF, sperm count, number of mature oocytes, and MII ratio.
However, the total motility was significantly higher in the
PICSI group (Table 1).
In the PICSI group, 26 couples vitrified all of their embry-
os, 15 couples had day 3 ET, and 159 couples had day 5 ET. In
the MACS group, 33 cases vitrified all of their embryos, 10
cases had day 3 ET, and 153 cases had day 5 ET. The average
number of embryos transferred per case was 2.28 ± 0.87 in the
PICSI group and 2.33 ± 0.81 in the MACS group (p =
0.5873).
The primary analysis showed that the ongoing pregnancy
rate of the PICSI group was 55.7% vs. 56.4% for the MACS
group (p = 0.8972) (Table 2). The pre-implantation parame-
ters of cleavage, blastulation, and good-quality blastulation
rates revealed no differences between both groups (Table 2).
The clinical pregnancy rate was 62.4% and 62.1% for PICSI
and MACS groups (p = 0.9548), respectively. In addition, im-
plantation rates also showed no difference (p = 0.9553).
While in the PICSI group one case had a biochemical preg-
nancy, two cases were recorded in the MACS group. Forty-
eight cases in the MACS group had multiple pregnancies (44
twins and 4 triplets), whereas 53 multiple pregnancies (52
twins and 1 triplet) were recorded in the PICSI group.
Sub-analysis according to the male age included 3 groups
(less than 35 years, 36 to 41 years, and older than 41 years)
(Table 3). This comparison showed no differences between
PICSI and MACS in any of the studied parameters (Table 3).
In addition, comparisons of the 3male age groups using PICSI
technique did not show any difference in cleavage (p = 0.623),
blastulation (p = 0.936), good-quality blastulation (p = 0.925),
clinical pregnancy (p = 0.528), implantation (p = 0.617), and
ongoing pregnancy rates (p = 0.891). Moreover, comparisons
of the 3 male groups using MACS also did not show differ-
ences in cleavage (p = 0.244), blastulation (p = 0.071), good-
Table 1 Patient characteristics
PICSI (n = 200) MACS (n = 196) p value
Types of infertility
Primary (%)* 57.3 63.4 0.31
Secondary (%)* 42.6 36.5
Male partner
Male age (years) 35.9 ± 6.2 36.2 ± 7.3 0.56
Current smokers (%)* 40.1 30.6 0.15
SDF (% ± SD) 28.5 ± 7.1 28.6 ± 7.2 0.9
Sperm count (× 106/ml) 28.7 ± 21.6 31.2 ± 20.1 0.23
Total motility (% ± SD) 50.9 ± 15.8 46.1 ± 14.9 0.002
Sexual abstinence (days) 1.76 ± 0.6 1.81 ± 0.6 0.67
Female partner
Female age (years) 30.1 ± 4 29.8 ± 3.9 0.45
MII oocytes/case 15.1 ± 8 15.3 ± 8.4 0.81
MII (%)* 82.7 ± 13.4 82 ± 12.6 0.63
Data are mean (SD) unless otherwise stated. n refers to the number of
patients for whom data were available. PICSI physiological
intracytoplasmic sperm injection, MACS magnetic-activated cell sorting,
SDF sperm DNA fragmentation, MII metaphase II oocytes. p values <
0.05 are considered significant
*Data are percentages only
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quality blastulation (p = 0.396), clinical pregnancy (p =
0.181), implantation (p = 0.187), and ongoing pregnancy rates
(p = 0.173).
Another sub-analysis was done where cases in each
group were categorized according to the female age (less
than 30 years and from 30 to 35 years) (Table 4). There
was no significant difference in SDF values between PICSI
and MACS group neither when the female age was less
than 30 years nor from 30 to 35 years (Table 4). There
was a significant difference in the ongoing pregnancy rate
of 51.3% vs. 69.5% for PICSI and MACS groups, respec-
tively (p = 0.015), in the same female age group < 30 years
(Table 4). Moreover, the MACS group had significantly
higher good-quality blastulation and clinical pregnancy
rates (Table 4). The analysis of females aged between 30
and 35 showed no significant difference in all of the stud-
ied parameters between PICSI and MACS, but the PICSI
group showed values near to be significant implantation
(p = 0.051), clinical pregnancy (p = 0.078), and ongoing
pregnancy rates (p = 0.09) (Table 4). Upon comparing dif-
ferent female age groups using the same technique, we
found no significant differences in any of the compared
parameters after using PICSI as a sperm selection.
However, MACS in females age less than 30 years showed
significantly higher good-quality blastulation (p = 0.04),
clinical pregnancy (p = 0.003), implantation (p = 0.02),
and ongoing pregnancy rates (p = 0.002) compared with
the female age group from 30 to 35 years.
Table 3 Trial outcomes analyzed according to the male age (years)



















Female age (years) 28.6 ± 3.4 27.8 ± 3.5 0.12 31.4 ± 3.2 31.8 ± 2.9 0.47 32.6 ± 3.6 32.2 ± 2.8 0.63
SDF (%) 27.6 ± 6.8 29 ± 7.5 0.15 28.6 ± 6.2 28.4 ± 6.7 0.86 31.4 ± 8.5 28.1 ± 6.4 0.09
MII 16.2 ± 8.4 15.7 ± 7.6 0.65 13.7 ± 7.5 14.9 ± 8.4 0.41 13.5 ± 6.9 15 ± 10.9 0.52
Primary outcome
Ongoing pregnancy rate (%)* 58.5 63.9 0.46 55.7 50 0.55 53.5 40 0.32
Secondary outcomes
Cleavage rate (% ± SD) 75.8 ± 16 75.3 ± 15.7 0.81 74.2 ± 17.6 76.6 ± 15.8 0.43 78.5 ± 21.3 68.4 ± 24.1 0.08
Blastulation rate (% ± D) 64.4 ± 18 63.2 ± 19.7 0.64 63.8 ± 19.1 67 ± 15.3 0.31 65.3 ± 18.2 56.9 ± 21.2 0.10
Good-quality blastulation rate (%
± SD)
63.5 ± 25.2 69.4 ± 24.3 0.08 64.7 ± 23 65.8 ± 30.3 0.82 62.7 ± 25.2 59.5 ± 39.5 0.70
Clinical pregnancy rate (%)* 65.9 68.6 0.70 59.6 59.2 0.97 57.1 47.8 0.50
Implantation rate (%)* 45.9 47.9 0.77 44.4 42.6 0.84 36.4 30.8 0.64
Data are mean (SD) unless otherwise stated. n refers to the number of patients for whom data were available.PICSI physiological intracytoplasmic sperm
injection,MACSmagnetic-activated cell sorting, SDF sperm DNA fragmentation,MII metaphase II oocytes. p values < 0.05 are considered significant
*Data are percentages only
Table 2 Primary analysis of pre-
implantation embryological and
clinical parameters comparing
PICSI and MACS groups
PICSI (n = 200) MACS (n = 196) p value
Primary outcome
Ongoing pregnancy (%)* 55.7% 56.4% 0.89
Secondary outcomes
Cleavage rate (% ± SD) 75.6 ± 17.3 74.7 ± 17.4 0.64
Blastulation rate (% ± SD) 64.3 ± 18.2 63.4 ± 18.8 0.62
Good-quality blastulation rate (% ± SD) 63.7 ± 24.4 66.3 ± 29.3 0.31
Clinical pregnancy rate (%)* 62.4% 62.1% 0.95
Implantation rate (%)* 40.3% 40.0% 0.95
Data are mean (SD) unless otherwise stated. n refers to the number of patients for whom data were available.
PICSI physiological intracytoplasmic sperm injection,MACSmagnetic-activated cell sorting. p values < 0.05 are
considered significant
*Data are percentages only
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Discussion
Identifying the paternal factors affecting infertility is critically
important for assisted reproduction because ICSI has allowed
men with abnormal SDF to successfully father children.
Hence, the male age may increase the risk of vertical trans-
mission of paternal genetic defects [4]. Sperm selection in
ICSI depends on viability, morphology, and gradient centri-
fugation; however, the main aim is to select sperm with lower
SDF to eliminate the detrimental effects of abnormal SDF [4,
9, 10]. The selection of spermatozoa is crucial in optimizing
ICSI outcomes and various techniques are recommended for
sperm selection in these patients. Among these techniques are
PICSI or MACS that are thought to select rather normal SDF
sperm for ICSI [38].
The value of using an advanced sperm selection technique
in ICSI has been studied by many researchers. Some support-
ed the usage of those techniques for indicated cases and re-
ported significant improvement in ICSI outcomes, while
others who studied their use in general ICSI patients and did
not show significant improvements. Ferreyra et al. [26] com-
pared the normal SDF group with the abnormal SDF semen
that was processed by MACS; they have found no significant
difference between both groups in fertilization, cleavage, blas-
tulation, pregnancy, implantation, and miscarriage rates. They
concluded that MACS can eliminate the negative effects of
abnormal SDF. Dirican et al. [23] reported significantly higher
cleavage and pregnancy rates after using MACS in men with
oligoasthenoteratozoospermia. A study by Worrilow et al.
[32] used PICSI dishes for sperm selection in 802 patients
and found a significant improvement in pregnancy loss rate
in patients with hyaluronan binding less than 65% (cutoff
value for using PICSI dishes). Also, Majumdar et al. [31]
reported an improvement, though not reaching significance,
in the miscarriage rate after using PICSI. Contrary to the pre-
vious researchers, Horta et al. [27] studied the effect of using
MACS on pregnancy, implantation, andmiscarriage rates, and
did not find any significant improvement in normozoospermic
or male factor patients; however, SDF assessment was not
carried out. Recently, Miller et al. [39] studied the effect of
PICSI on the live birth rate in a parallel two-group prospective
randomized trial; the study included all males undergoing
ICSI and found that PICSI did not increase the live birth rate
compared with ICSI. It is worth noting that those who found
improvement in clinical outcomes have applied sperm selec-
tion techniques only to patients with abnormal SDF, while
those who applied sperm selection as a routine procedure in
ICSI have not found an improvement in their clinical out-
comes. The study by Miller et al. [39] showed that 72% of
the cases selected for PICSI already had a hyaluronan binding
score greater than 65% (i.e., not indicated for PICSI). Hence, it
seems like the patient’s indication for a sperm selection tech-
nique is the key to improve their clinical outcomes.
The purpose of our study was to look at which of the two
sperm selection techniques (PICSI/MACS) will lead to better
clinical outcomes in patients with abnormal SDF. We found
that there are no significant differences between PICSI and
MACS in all of the studied parameters. Sub-analysis accord-
ing to the male age showed no significant differences between
PICSI and MACS in the same male age group, or even by
comparing the 3 different age groups using the same tech-
nique (Table 3). This means that either PICSI or MACS can
be performed with the same efficiency at different male ages.
However, sub-analysis according to the female age showed
Table 4 Trial outcomes analyzed according to female age
F age < 30 F age 30–35
PICSI (n = 83) MACS (n = 86) p value PICSI (n = 117) MACS (n = 110) p value
Male age (years) 34.5 ± 6.5 33.1 ± 7.2 0.18 38.0 ± 5.8 38.8 ± 7.2 0.32
SDF (% ± SD) 28.0 ± 7.3 27.8 ± 6.2 0.87 28.7 ± 6.9 29.1 ± 7.8 0.70
MII (%) 81.8 ± 13.7 79.1 ± 13.9 0.29 83.3 ± 13.2 83.8 ± 11.3 0.76
Primary outcome
Ongoing pregnancy rate (%)* 51.3% 69.5% 0.01 58.8% 47.8% 0.09
Secondary outcomes
Cleavage rate (% ± SD) 77.0 ± 14.4 75.2 ± 15.8 0.43 74.7 ± 19.1 74.4 ± 18.6 0.88
Blastulation rate (% ± SD) 63.4 ± 18.7 63.7 ± 19.9 0.91 64.9 ± 17.9 63.1 ± 17.9 0.44
Good-quality blastulation rate (% ± SD) 62.9 ± 24.7 71.1 ± 25.4 0.03 64.2 ± 24.3 62.8 ± 31.6 0.69
Clinical pregnancy rate (%)* 58.3% 73.9% 0.03 64.7% 53.2% 0.07
Implantation rate (%)* 37.3% 48.7% 0.1 46% 33.3% 0.05
Data are mean (SD) unless otherwise stated. n refers to the number of patients for whom data were available.PICSI physiological intracytoplasmic sperm
injection, MACS magnetic-activated cell sorting. p values < 0.05 are considered significant
*Data are percentages only
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that the MACS group had significantly higher good-quality
blastulation, clinical pregnancy, and ongoing pregnancy rates
than the PICSI group when the female age was less than
30 years (Table 4). Patients allocated to the PICSI group
showed a tendency of higher implantation, pregnancy, and
ongoing pregnancy rates when the female age is between 30
and 35 years. On the other hand, MACS showed significantly
higher good-quality blastulation, implantation, clinical preg-
nancy, and ongoing pregnancy rates in the female age group
less than 30 compared with the older female age group in
MACS, while PICSI did not show a significant difference in
the outcomes in both female age groups (Table 4).
The process of fertilization in ICSI includes the following
steps: oocyte activation, sperm chromatin de-condensation,
sperm Aster formation, syngamy, and ends with mitosis
[40]. Sperm chromatin de-condensation plays a vital part in
this cascade of events [41]. The process of chromatin de-
condensation is very much affected by the oocyte’s helping
mechanisms [42], which are dependent on oocyte’s grades of
maturity and quality, and are both affected by the maternal age
[35, 36]. The first step in chromatin de-condensation, reorga-
nization, and activation of paternal genome is mediated by an
enzyme (splicing kinase SRPK1), which only present in the
oocyte [43]; it also plays a role in synchronizing the remodel-
ing of paternal genome with that of the maternal genome [43].
PICSI and MACS have different mechanisms for sperm se-
lection [38]. MACS-selected sperm display lower SDF, de-
creased apoptosis, and higher early fertilization potential than
conventional ICSI [44, 21, 24, 27]. This can be explained by
early sperm chromatin de-condensation [44]. On the other
hand, PICSI does not select sperm according to apoptosis,
but rather upon their maturity and hyaluronan binding [45].
It does appear that the advantage of MACS in sperm selection
becomes much clearer depending on the female age as a proxy
of oocyte quality [35]. Studies that have looked at oocyte
quality reflected by meiotic errors and the genesis of human
aneuploidy showed that the oocyte quality is better at younger
ages below 30 in comparison with age beyond 30 [46].
Therefore, this supports our finding that MACS-selected
sperm result in better pre-implantation embryogenesis than
PICSI-selected sperm when the female age is less than
30 years.
The efficiency of sperm selection techniques is still debat-
able and there are not enough clinical trials comparing differ-
ent techniques. Screening the literature retrospectively, only
one study by Troya et al. [47] compared two different sperm
selection techniques, where they compared PICSI and MACS
and found that MACS had significantly higher fertilization
and clinical pregnancy rates. When the female age is less than
30 years, our results are consistent with the study by Troya
and coworkers [47], where the mean female age was
36.9 years. There are differences between both studies where
we included a higher number of patients (396 patients), which
is statistically powered to show the difference, while Troya
et al. included only 136 patients. Moreover, their main end-
point was the clinical pregnancy rate, while we reported the
implantation rate and extended the evaluation of pregnancy to
the ongoing pregnancy rate, since abnormal SDF may cause
later problems like miscarriage [12]. We used a direct method
(TUNEL) for the evaluation of SDF instead of their indirect
method (Sperm chromatin dispersion) [48]. In addition, they
did not measure the SDF of patients before randomization.
While this study has several strengths such as clearly de-
fined outcomes, statistically powered to show the difference,
and it is the largest registered clinical trial comparing two
different sperm selection techniques, on the other hand, the
limitations of the study include no control since it was very
difficult to recruit patients with abnormal SDF. Another ad-
vantage would have been if the SDF could have been per-
formed on the same ejaculates that have been used for injec-
tion. In addition, it would be better if the follow-up of the
outcomes was extended to the live birth rate, and this will be
considered in our future research plans.
Conclusion
MACS and PICSI are suitable and efficient tools for human
sperm selection in patients undergoing ICSI with abnormal
SDF. Both techniques showed approximately similar results
in the primary analysis. MACS can achieve higher good-
quality blastulation, clinical pregnancy, and ongoing pregnan-
cy rates in females age less than 30, while PICSI is trending to
have higher implantation, clinical pregnancy, and ongoing
pregnancy rate in female age between 30 and 35.
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